For General Information: (740) 374-1400

24 Hour Nurse Line: (844) 474-6522

Filter by Custom Post Type
About Us
Careers
Community
Locations
Memorial Health Foundation
News
Pages
Patient and Visitors
Providers
Services

X


Rhabdomyolysis from statins: What's the risk?

February, 14th, 2025

Question

How do you know if you have rhabdomyolysis from statin use, and how likely is it?


Summary

Rhabdomyolysis is a rare but potentially life-threatening side effect of statins.


Answer

, Answer Section, ,

Although mild muscle pain is a relatively common side effect of statins, some people who take statin medications to lower their cholesterol may have severe muscle pain. This intense pain may be a symptom of rhabdomyolysis (rab-doe-my-OL-ih-sis), a rare condition that causes muscle cells to break down.

The most common signs and symptoms of rhabdomyolysis include:

  • Severe muscle aching throughout the entire body
  • Muscle weakness
  • Dark or cola-colored urine

The higher the dose of statins, the higher the risk of rhabdomyolysis becomes. The risk also increases if certain drugs — including cyclosporine (Sandimmune) and gemfibrozil (Lopid) — are taken in combination with statins. However, the risk of developing rhabdomyolysis from statin therapy is very low, around 1.5 for each 100,000 people taking statins. Rhabdomyolysis or milder forms of muscle inflammation from statins can be diagnosed with a blood test measuring levels of the enzyme creatinine kinase.

If you notice moderate or severe muscle aches after starting to take a statin, contact your doctor. If you have signs and symptoms of rhabdomyolysis, stop taking your statin medication immediately and seek medical treatment right away. If necessary, your doctor may take steps to help prevent kidney damage and other complications.


Sign Up For Our Community HealthLine Magazine

Stay informed, inspired, and connected with the Community HealthLine magazine! View past and newest editions conveniently available online, or sign up for a FREE printed version.

Subscribe